Type II kinase inhibitors show an unexpected inhibition mode against Parkinson's disease-linked LRRK2 mutant G2019S

Biochemistry

Volumn 52, Issue 10, 2013, Pages 1725-1736

  Liu, Min ^a   Bender, Samantha A ^b   Cuny, Gregory D ^a   Sherman, Woody ^d   Glicksman, Marcie ^a   Ray, Soumya S ^a,b,c,e  

^a The Harvard Center for Neurodegeneration & Repair   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d SCHRÖDINGER INC   (United States)

^e Proteus Discovery Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATION LOOPS; CONFORMATIONAL BARRIERS; ENHANCED SAMPLINGS; INHIBITION MECHANISMS; LOOP DYNAMICS; METADYNAMICS; MUTANT ENZYMES; TYPE II KINASE INHIBITOR;

HYDROGEN BONDS; NEURODEGENERATIVE DISEASES;

ENZYMES;

BOSUTINIB; GSK3 13; IMATINIB; LEUCINE RICH REPEAT KINASE 2; PONATINIB; PROTEIN SERINE THREONINE KINASE INHIBITOR; SORAFENIB; UNCLASSIFIED DRUG;

ALLOSTERISM; ARTICLE; CONTROLLED STUDY; ENZYME CONFORMATION; HYDROGEN BOND; MUTATION; PARKINSON DISEASE; PHENOTYPE; PRIORITY JOURNAL; WILD TYPE;

ALLOSTERIC SITE; AMINO ACID MOTIFS; AMINO ACID SUBSTITUTION; BINDING SITES; ENZYME STABILITY; HUMANS; HYDROGEN BONDING; KINETICS; MODELS, MOLECULAR; MOLECULAR DYNAMICS SIMULATION; MUTANT PROTEINS; PARKINSON DISEASE; PROTEIN CONFORMATION; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES;

EID: 84874967177     PISSN: 00062960     EISSN: 15204995     Source Type: Journal    
DOI: 10.1021/bi3012077     Document Type: Article

References (88)

1. Bosco, D. A., LaVoie, M. J., Petsko, G. A., and Ringe, D. (2011) Proteostasis and movement disorders: Parkinson's disease and amyotrophic lateral sclerosis Cold Spring Harbor Perspect. Biol. 3, a007500
2. Martin, I., Dawson, V. L., and Dawson, T. M. (2011) Recent Advances in the Genetics of Parkinson's Disease Annu. Rev. Genomics Hum. Genet. 12, 301-325
3. Hardy, J., Cookson, M. R., and Singleton, A. (2003) Genes and parkinsonism Lancet Neurol. 2, 221-228
4. Cookson, M. R. (2003) Pathways to Parkinsonism Neuron 37, 7-10
5. Benamer, H. T. (2008) The ancestry of LRRK2 Gly2019Ser parkinsonism Lancet Neurol. 7, 769-770, author reply 770-761
6. Cookson, M. R. (2010) The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease Nat. Rev. Neurosci. 11, 791-797
7. Cookson, M. R., Dauer, W., Dawson, T., Fon, E. A., Guo, M., and Shen, J. (2007) The roles of kinases in familial Parkinson's disease J. Neurosci. 27, 11865-11868
8. Clark, L. N., Wang, Y., Karlins, E., Saito, L., Mejia-Santana, H., Harris, J., Louis, E. D., Cote, L. J., Andrews, H., Fahn, S., Waters, C., Ford, B., Frucht, S., Ottman, R., and Marder, K. (2006) Frequency of LRRK2 mutations in early- and late-onset Parkinson disease Neurology 67, 1786-1791
9. Cookson, M. R. and Bandmann, O. (2010) Parkinson's disease: Insights from pathways Hum. Mol. Genet. 19, R21-R27
10. Cookson, M. R., Xiromerisiou, G., and Singleton, A. (2005) How genetics research in Parkinson's disease is enhancing understanding of the common idiopathic forms of the disease Curr. Opin. Neurol. 18, 706-711
11. Correia Guedes, L., Ferreira, J. J., Rosa, M. M., Coelho, M., Bonifati, V., and Sampaio, C. (2010) Worldwide frequency of G2019S LRRK2 mutation in Parkinson's disease: A systematic review Parkinsonism and Related Disorders 16, 237-242
12. Dachsel, J. C. and Farrer, M. J. (2010) LRRK2 and Parkinson disease Arch. Neurol. 67, 542-547
13. Mata, I. F., Wedemeyer, W. J., Farrer, M. J., Taylor, J. P., and Gallo, K. A. (2006) LRRK2 in Parkinson's disease: Protein domains and functional insights Trends Neurosci. 29, 286-293
14. Daniels, V., Vancraenenbroeck, R., Law, B. M., Greggio, E., Lobbestael, E., Gao, F., De Maeyer, M., Cookson, M. R., Harvey, K., Baekelandt, V., and Taymans, J. M. (2011) Insight into the mode of action of the LRRK2 Y1699C pathogenic mutant J. Neurochem. 116, 304-315
15. Greggio, E., Taymans, J. M., Zhen, E. Y., Ryder, J., Vancraenenbroeck, R., Beilina, A., Sun, P., Deng, J., Jaffe, H., Baekelandt, V., Merchant, K., and Cookson, M. R. (2009) The Parkinson's disease kinase LRRK2 autophosphorylates its GTPase domain at multiple sites Biochem. Biophys. Res. Commun. 389, 449-454
16. Lewis, P. A., Greggio, E., Beilina, A., Jain, S., Baker, A., and Cookson, M. R. (2007) The R1441C mutation of LRRK2 disrupts GTP hydrolysis Biochem. Biophys. Res. Commun. 357, 668-671
17. Luzon-Toro, B., Rubio de la Torre, E., Delgado, A., Perez-Tur, J., and Hilfiker, S. (2007) Mechanistic insight into the dominant mode of the Parkinson's disease-associated G2019S LRRK2 mutation Hum. Mol. Genet. 16, 2031-2039
18. West, A. B., Moore, D. J., Biskup, S., Bugayenko, A., Smith, W. W., Ross, C. A., Dawson, V. L., and Dawson, T. M. (2005) Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity Proc. Natl. Acad. Sci. U.S.A. 102, 16842-16847
19. Smith, W. W., Pei, Z., Jiang, H., Dawson, V. L., Dawson, T. M., and Ross, C. A. (2006) Kinase activity of mutant LRRK2 mediates neuronal toxicity Nat. Neurosci. 9, 1231-1233
20. Greggio, E., Jain, S., Kingsbury, A., Bandopadhyay, R., Lewis, P., Kaganovich, A., van der Brug, M. P., Beilina, A., Blackinton, J., Thomas, K. J., Ahmad, R., Miller, D. W., Kesavapany, S., Singleton, A., Lees, A., Harvey, R. J., Harvey, K., and Cookson, M. R. (2006) Kinase activity is required for the toxic effects of mutant LRRK2/dardarin Neurobiol. Dis. 23, 329-341
21. Deng, X., Dzamko, N., Prescott, A., Davies, P., Liu, Q., Yang, Q., Lee, J. D., Patricelli, M. P., Nomanbhoy, T. K., Alessi, D. R., and Gray, N. S. (2011) Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2 Nat. Chem. Biol. 7, 203-205
22. Maekawa, T., Mori, S., Sasaki, Y., Miyajima, T., Azuma, S., Ohta, E., and Obata, F. (2012) The I2020T leucine-rich repeat kinase 2 transgenic mouse exhibits impaired locomotive ability accompanied by dopaminergic neuron abnormalities Mol. Neurodegener. 7, 15
23. Ujiie, S., Hatano, T., Kubo, S. I., Imai, S., Sato, S., Uchihara, T., Yagishita, S., Hasegawa, K., Kowa, H., Sakai, F., and Hattori, N. (2012) LRRK2 I2020T mutation is associated with tau pathology Parkinsonism and Related Disorders 18, 819-823
24. Deng, H., Le, W., Davidson, A. L., Xie, W., and Jankovic, J. (2006) The LRRK2 I2012T, G2019S and I2020T mutations are not common in patients with essential tremor Neurosci. Lett. 407, 97-100
25. Lu, C. S., Simons, E. J., Wu-Chou, Y. H., Fonzo, A. D., Chang, H. C., Chen, R. S., Weng, Y. H., Rohe, C. F., Breedveld, G. J., Hattori, N., Gasser, T., Oostra, B. A., and Bonifati, V. (2005) The LRRK2 I2012T, G2019S, and I2020T mutations are rare in Taiwanese patients with sporadic Parkinson's disease Parkinsonism and Related Disorders 11, 521-522
26. Taylor, S. S. and Kornev, A. P. (2011) Protein kinases: Evolution of dynamic regulatory proteins Trends Biochem. Sci. 36, 65-77
27. Taylor, S. S., Kim, C., Vigil, D., Haste, N. M., Yang, J., Wu, J., and Anand, G. S. (2005) Dynamics of signaling by PKA Biochim. Biophys. Acta 1754, 25-37
28. Johnson, D. A., Akamine, P., Radzio-Andzelm, E., Madhusudan, M., and Taylor, S. S. (2001) Dynamics of cAMP-dependent protein kinase Chem. Rev. 101, 2243-2270
29. Taylor, S. S., Radzio-Andzelm, E., Madhusudan, Cheng, X., Ten Eyck, L., and Narayana, N. (1999) Catalytic subunit of cyclic AMP-dependent protein kinase: Structure and dynamics of the active site cleft Pharmacol. Ther. 82, 133-141
30. Taylor, S. S. and Radzio-Andzelm, E. (1997) Protein kinase inhibition: Natural and synthetic variations on a theme Curr. Opin. Chem. Biol. 1, 219-226
31. Cox, S., Radzio-Andzelm, E., and Taylor, S. S. (1994) Domain movements in protein kinases Curr. Opin. Struct. Biol. 4, 893-901
32. Besker, N. and Gervasio, F. L. (2012) Using metadynamics and path collective variables to study ligand binding and induced conformational transitions Methods Mol. Biol. 819, 501-513
33. Fiorin, G., Pastore, A., Carloni, P., and Parrinello, M. (2006) Using metadynamics to understand the mechanism of calmodulin/target recognition at atomic detail Biophys. J. 91, 2768-2777
34. Masetti, M., Cavalli, A., Recanatini, M., and Gervasio, F. L. (2009) Exploring complex protein-ligand recognition mechanisms with coarse metadynamics J. Phys. Chem. B 113, 4807-4816
35. Liu, M., Kang, S., Ray, S., Jackson, J., Zaitsev, A. D., Gerber, S. A., Cuny, G. D., and Glicksman, M. A. (2011) Kinetic, mechanistic, and structural modeling studies of truncated wild-type leucine-rich repeat kinase 2 and the G2019S mutant Biochemistry 50, 9399-9408
36. Fiser, A. and Sali, A. (2003) ModLoop: Automated modeling of loops in protein structures Bioinformatics 19, 2500-2501
37. John, B. and Sali, A. (2003) Comparative protein structure modeling by iterative alignment, model building and model assessment Nucleic Acids Res. 31, 3982-3992
38. Eswar, N., John, B., Mirkovic, N., Fiser, A., Ilyin, V. A., Pieper, U., Stuart, A. C., Marti-Renom, M. A., Madhusudhan, M. S., Yerkovich, B., and Sali, A. (2003) Tools for comparative protein structure modeling and analysis Nucleic Acids Res. 31, 3375-3380
39. Sanchez, R. and Sali, A. (1997) Evaluation of comparative protein structure modeling by MODELLER-3 Proteins 1 (Suppl.) 50-58
40. Friesner, R. A., Banks, J. L., Murphy, R. B., Halgren, T. A., Klicic, J. J., Mainz, D. T., Repasky, M. P., Knoll, E. H., Shelley, M., Perry, J. K., Shaw, D. E., Francis, P., and Shenkin, P. S. (2004) Glide: A new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy J. Med. Chem. 47, 1739-1749
41. Sherman, W., Day, T., Jacobson, M. P., Friesner, R. A., and Farid, R. (2006) Novel procedure for modeling ligand/receptor induced fit effects J. Med. Chem. 49, 534-553
42. Jacobson, M. P., Pincus, D. L., Rapp, C. S., Day, T. J., Honig, B., Shaw, D. E., and Friesner, R. A. (2004) A hierarchical approach to all-atom protein loop prediction Proteins 55, 351-367
43. Emekli, U., Schneidman-Duhovny, D., Wolfson, H. J., Nussinov, R., and Haliloglu, T. (2008) HingeProt: Automated prediction of hinges in protein structures Proteins 70, 1219-1227
44. Lill, M. A. and Danielson, M. L. (2011) Computer-aided drug design platform using PyMOL J. Comput.-Aided Mol. Des. 25, 13-19
45. Shaw, D. E., Maragakis, P., Lindorff-Larsen, K., Piana, S., Dror, R. O., Eastwood, M. P., Bank, J. A., Jumper, J. M., Salmon, J. K., Shan, Y., and Wriggers, W. (2010) Atomic-level characterization of the structural dynamics of proteins Science 330, 341-346
46. Guvench, O. and MacKerell, A. D., Jr. (2008) Comparison of protein force fields for molecular dynamics simulations Methods Mol. Biol. 443, 63-88
47. Barducci, A., Bonomi, M., and Parrinello, M. (2010) Linking well-tempered metadynamics simulations with experiments Biophys. J. 98, L44-L46
48. Barducci, A., Bussi, G., and Parrinello, M. (2008) Well-tempered metadynamics: A smoothly converging and tunable free-energy method Phys. Rev. Lett. 100, 020603
49. Barducci, A., Chelli, R., Procacci, P., Schettino, V., Gervasio, F. L., and Parrinello, M. (2006) Metadynamics simulation of prion protein: β-structure stability and the early stages of misfolding J. Am. Chem. Soc. 128, 2705-2710
50. Berteotti, A., Barducci, A., and Parrinello, M. (2011) Effect of urea on the β-hairpin conformational ensemble and protein denaturation mechanism J. Am. Chem. Soc. 133, 17200-17206
51. Bonomi, M., Barducci, A., Gervasio, F. L., and Parrinello, M. (2010) Multiple routes and milestones in the folding of HIV-1 protease monomer PLoS One 5, e13208
52. Bonomi, M. and Parrinello, M. (2010) Enhanced sampling in the well-tempered ensemble Phys. Rev. Lett. 104, 190601
53. Branduardi, D., Gervasio, F. L., and Parrinello, M. (2007) From A to B in free energy space J. Chem. Phys. 126, 054103
54. Bussi, G., Laio, A., and Parrinello, M. (2006) Equilibrium free energies from nonequilibrium metadynamics Phys. Rev. Lett. 96, 090601
55. Leone, V., Marinelli, F., Carloni, P., and Parrinello, M. (2010) Targeting biomolecular flexibility with metadynamics Curr. Opin. Struct. Biol. 20, 148-154
56. Limongelli, V., Bonomi, M., Marinelli, L., Gervasio, F. L., Cavalli, A., Novellino, E., and Parrinello, M. (2010) Molecular basis of cyclooxygenase enzymes (COXs) selective inhibition Proc. Natl. Acad. Sci. U.S.A. 107, 5411-5416
57. Limongelli, V., Marinelli, L., Cosconati, S., La Motta, C., Sartini, S., Mugnaini, L., Da Settimo, F., Novellino, E., and Parrinello, M. (2012) Sampling protein motion and solvent effect during ligand binding Proc. Natl. Acad. Sci. U.S.A. 109, 1467-1472
58. Liu, M., Choi, S., Cuny, G. D., Ding, K., Dobson, B. C., Glicksman, M. A., Auerbach, K., and Stein, R. L. (2008) Kinetic studies of Cdk5/p25 kinase: Phosphorylation of tau and complex inhibition by two prototype inhibitors Biochemistry 47, 8367-8377
59. Levinson, N. M. and Boxer, S. G. (2012) Structural and spectroscopic analysis of the kinase inhibitor bosutinib and an isomer of bosutinib binding to the Abl tyrosine kinase domain PLoS One 7, e29828
60. Leaver-Fay, A., Tyka, M., Lewis, S. M., Lange, O. F., Thompson, J., Jacak, R., Kaufman, K., Renfrew, P. D., Smith, C. A., Sheffler, W., Davis, I. W., Cooper, S., Treuille, A., Mandell, D. J., Richter, F., Ban, Y. E., Fleishman, S. J., Corn, J. E., Kim, D. E., Lyskov, S., Berrondo, M., Mentzer, S., Popovic, Z., Havranek, J. J., Karanicolas, J., Das, R., Meiler, J., Kortemme, T., Gray, J. J., Kuhlman, B., Baker, D., and Bradley, P. (2011) ROSETTA3: An object-oriented software suite for the simulation and design of macromolecules Methods Enzymol. 487, 545-574
61. Kiefer, F., Arnold, K., Kunzli, M., Bordoli, L., and Schwede, T. (2009) The SWISS-MODEL Repository and associated resources Nucleic Acids Res. 37, D387-D392
62. Eswar, N., Eramian, D., Webb, B., Shen, M. Y., and Sali, A. (2008) Protein structure modeling with MODELLER Methods Mol. Biol. 426, 145-159
63. Gilsbach, B. K., Ho, F. Y., Vetter, I. R., van Haastert, P. J., Wittinghofer, A., and Kortholt, A. (2012) Roco kinase structures give insights into the mechanism of Parkinson disease-related leucine-rich-repeat kinase 2 mutations Proc. Natl. Acad. Sci. U.S.A. 109, 10322-10327
64. Zhu, K., Pincus, D. L., Zhao, S., and Friesner, R. A. (2006) Long loop prediction using the protein local optimization program Proteins 65, 438-452
65. Aasly, J. O., Toft, M., Fernandez-Mata, I., Kachergus, J., Hulihan, M., White, L. R., and Farrer, M. (2005) Clinical features of LRRK2-associated Parkinson's disease in central Norway Ann. Neurol. 57, 762-765
66. Abdalla-Carvalho, C. B., Santos-Reboucas, C. B., Guimaraes, B. C., Campos, M., Pereira, J. S., de Rosso, A. L., Nicaretta, D. H., Marinho e Silva, M., dos Santos, M. J., and Pimentel, M. M. (2010) Genetic analysis of LRRK2 functional domains in Brazilian patients with Parkinson's disease Eur. J. Neurol. 17, 1479-1481
67. Alcalay, R. N., Mejia-Santana, H., Tang, M. X., Rosado, L., Verbitsky, M., Kisselev, S., Ross, B. M., Louis, E. D., Comella, C. L., Colcher, A., Jennings, D., Nance, M. A., Bressman, S., Scott, W. K., Tanner, C., Mickel, S. F., Andrews, H. F., Waters, C. H., Fahn, S., Cote, L. J., Frucht, S. J., Ford, B., Rezak, M., Novak, K., Friedman, J. H., Pfeiffer, R., Marsh, L., Hiner, B., Siderowf, A., Caccappolo, E., Ottman, R., Clark, L. N., and Marder, K. S. (2009) Motor phenotype of LRRK2 G2019S carriers in early-onset Parkinson disease Arch. Neurol. 66, 1517-1522
68. Bardien, S., Marsberg, A., Keyser, R., Lombard, D., Lesage, S., Brice, A., and Carr, J. (2010) LRRK2 G2019S mutation: Frequency and haplotype data in South African Parkinson's disease patients J. Neural Transm. 117, 847-853
69. Bar-Shira, A., Hutter, C. M., Giladi, N., Zabetian, C. P., and Orr-Urtreger, A. (2009) Ashkenazi Parkinson's disease patients with the LRRK2 G2019S mutation share a common founder dating from the second to fifth centuries Neurogenetics 10, 355-358
70. Belarbi, S., Hecham, N., Lesage, S., Kediha, M. I., Smail, N., Benhassine, T., Ysmail-Dahlouk, F., Lohman, E., Benhabyles, B., Hamadouche, T., Assami, S., Brice, A., and Tazir, M. (2010) LRRK2 G2019S mutation in Parkinson's disease: A neuropsychological and neuropsychiatric study in a large Algerian cohort Parkinsonism and Related Disorders 16, 676-679
71. Benamer, H. T. and de Silva, R. (2010) LRRK2 G2019S in the North African population: A review Eur. Neurol. 63, 321-325
72. Bonifati, V. (2006) Parkinson's disease: The LRRK2-G2019S mutation: Opening a novel era in Parkinson's disease genetics Eur. J. Hum. Genet. 14, 1061-1062
73. Bras, J., Guerreiro, R., Ribeiro, M., Morgadinho, A., Januario, C., Dias, M., Calado, A., Semedo, C., Oliveira, C., Hardy, J., and Singleton, A. (2008) Analysis of Parkinson disease patients from Portugal for mutations in SNCA, PRKN, PINK1 and LRRK2 BMC Neurol. 8, 1
74. Carmine Belin, A., Westerlund, M., Sydow, O., Lundstromer, K., Hakansson, A., Nissbrandt, H., Olson, L., and Galter, D. (2006) Leucine-rich repeat kinase 2 (LRRK2) mutations in a Swedish Parkinson cohort and a healthy nonagenarian Mov. Disord. 21, 1731-1734
75. Change, N., Mercier, G., and Lucotte, G. (2008) Genetic screening of the G2019S mutation of the LRRK2 gene in Southwest European, North African, and Sephardic Jewish subjects Genet. Test. 12, 333-339
76. Cho, J. W., Kim, S. Y., Park, S. S., and Jeon, B. S. (2009) The G2019S LRRK2 Mutation is Rare in Korean Patients with Parkinson's Disease and Multiple System Atrophy J. Clin. Neurol. 5, 29-32
77. Criscuolo, C., De Rosa, A., Guacci, A., Simons, E. J., Breedveld, G. J., Peluso, S., Volpe, G., Filla, A., Oostra, B. A., Bonifati, V., and De Michele, G. (2011) The LRRK2 R1441C mutation is more frequent than G2019S in Parkinson's disease patients from Southern Italy Mov. Disord. 26, 1732-1736
78. Deng, H., Le, W., Guo, Y., Hunter, C. B., Xie, W., and Jankovic, J. (2005) Genetic and clinical identification of Parkinson's disease patients with LRRK2 G2019S mutation Ann. Neurol. 57, 933-934
79. Di Fonzo, A., Tassorelli, C., De Mari, M., Chien, H. F., Ferreira, J., Rohe, C. F., Riboldazzi, G., Antonini, A., Albani, G., Mauro, A., Marconi, R., Abbruzzese, G., Lopiano, L., Fincati, E., Guidi, M., Marini, P., Stocchi, F., Onofrj, M., Toni, V., Tinazzi, M., Fabbrini, G., Lamberti, P., Vanacore, N., Meco, G., Leitner, P., Uitti, R. J., Wszolek, Z. K., Gasser, T., Simons, E. J., Breedveld, G. J., Goldwurm, S., Pezzoli, G., Sampaio, C., Barbosa, E., Martignoni, E., Oostra, B. A., and Bonifati, V. (2006) Comprehensive analysis of the LRRK2 gene in sixty families with Parkinson's disease Eur. J. Hum. Genet. 14, 322-331
80. Funalot, B., Nichols, W. C., Perez-Tur, J., Mercier, G., and Lucotte, G. (2006) Genetic screening for two LRRK2 mutations in French patients with idiopathic Parkinson's disease Genet. Test. 10, 290-293
81. Gandhi, P. N., Chen, S. G., and Wilson-Delfosse, A. L. (2009) Leucine-rich repeat kinase 2 (LRRK2): A key player in the pathogenesis of Parkinson's disease J. Neurosci. Res. 87, 1283-1295
82. Gao, L., Gomez-Garre, P., Diaz-Corrales, F. J., Carrillo, F., Carballo, M., Palomino, A., Diaz-Martin, J., Mejias, R., Vime, P. J., Lopez-Barneo, J., and Mir, P. (2009) Prevalence and clinical features of LRRK2 mutations in patients with Parkinson's disease in southern Spain Eur. J. Neurol. 16, 957-960
83. Goldwurm, S., Di Fonzo, A., Simons, E. J., Rohe, C. F., Zini, M., Canesi, M., Tesei, S., Zecchinelli, A., Antonini, A., Mariani, C., Meucci, N., Sacilotto, G., Sironi, F., Salani, G., Ferreira, J., Chien, H. F., Fabrizio, E., Vanacore, N., Dalla Libera, A., Stocchi, F., Diroma, C., Lamberti, P., Sampaio, C., Meco, G., Barbosa, E., Bertoli-Avella, A. M., Breedveld, G. J., Oostra, B. A., Pezzoli, G., and Bonifati, V. (2005) The G6055A (G2019S) mutation in LRRK2 is frequent in both early and late onset Parkinson's disease and originates from a common ancestor J. Med. Genet. 42, e65
84. Goldwurm, S., Tunesi, S., Tesei, S., Zini, M., Sironi, F., Primignani, P., Magnani, C., and Pezzoli, G. (2011) Kin-cohort analysis of LRRK2-G2019S penetrance in Parkinson's disease Mov. Disord. 26, 2144-2145
85. Ishihara, L., Gibson, R. A., Warren, L., Amouri, R., Lyons, K., Wielinski, C., Hunter, C., Swartz, J. E., Elango, R., Akkari, P. A., Leppert, D., Surh, L., Reeves, K. H., Thomas, S., Ragone, L., Hattori, N., Pahwa, R., Jankovic, J., Nance, M., Freeman, A., Gouider-Khouja, N., Kefi, M., Zouari, M., Ben Sassi, S., Ben Yahmed, S., El Euch-Fayeche, G., Middleton, L., Burn, D. J., Watts, R. L., and Hentati, F. (2007) Screening for Lrrk2 G2019S and clinical comparison of Tunisian and North American Caucasian Parkinson's disease families Mov. Disord. 22, 55-61
86. Ramsden, N., Perrin, J., Ren, Z., Lee, B. D., Zinn, N., Dawson, V. L., Tam, D., Bova, M., Lang, M., Drewes, G., Bantscheff, M., Bard, F., Dawson, T. M., and Hopf, C. (2011) Chemoproteomics-based design of potent LRRK2-selective lead compounds that attenuate Parkinson's disease-related toxicity in human neurons ACS Chem. Biol. 6, 1021-1028
87. Kramer, T., Lomonte, F., Goring, S., Amombo, G. M. O., and Schmidt, B. (2012) Small molecule kinase inhibitors for LRRK2 and their application to parkinson's disease models ACS Chem. Neurosci. 3, 151-160
88. Chen, H., Chan, B. K., Drummond, J., Estrada, A. A., Gunzner-Toste, J., Liu, X., Liu, Y., Moffat, J., Shore, D., Sweeney, Z. K., Tran, T., Wang, S., Zhao, G., Zhu, H., and Burdick, D. J. (2012) Discovery of Selective LRRK2 Inhibitors Guided by Computational Analysis and Molecular Modeling J. Med. Chem. 55, 5536-5545